phospholipase B domain containing 1Genealiases: LyLAP · PLBL1
Q-omics provides the consensus-scored PLBD1 profile across patient tissues and cancer cell-line models. PLBD1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLBD1 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, PLBD1 protein abundance shows 22,975 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where PLBD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLBD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLBD1 survival associations across molecular data types. PLBD1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLBD1 RNA expression–survival associations across cancer types. High PLBD1 expression shows unfavorable associations in PAAD, LGG and LIHC, but favorable associations in KIRC, HNSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLBD1 RNA expression.
This table summarizes PLBD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PLBD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLBD1 shows lower tumor expression in LUAD, BRCA and LUSC and higher tumor expression in STAD, CHOL and BLCA. The LUAD box plot shows higher PLBD1 RNA expression in normal versus tumor tissue (log2 FC = −1.375, t-test p < 0.001).
This table shows molecular features associated with PLBD1 in patient tissues and cancer cell lines. In patient samples, PLBD1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLBD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
